Piramal Pharma acquires additional 40.67% stake in Yapan Bio, makes it subsidiary
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma has completed acquisition of additional 40.67% stake (1,46,400 equity shares) in Yapan Bio for about Rs 76 crore cash. Its shareholding has risen from 33.33% to 74%, making Yapan a subsidiary instead of an associate. Yapan is a CDMO specializing in vaccine and biologic process development and Phase I/II GMP manufacturing. Its revenue was Rs 26.91 cr (FY24), Rs 54.40 cr (FY25), Rs 26.34 cr (FY26). PPL will integrate Yapan's large molecule capabilities into its offerings.
Strengthens biologics and vaccine CDMO capabilities as Yapan becomes a subsidiary. Revenue contribution is modest, but strategic value in large molecule space is meaningful.